How Kidron was paid
$2.1M in total for fiscal 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Nadav KidronPresident, Chief Executive Officer and Chairman | $540,145 | $270,767 | $1,224,760 | $62,017 | $2,097,689 |
| Dr. Miriam KidronChief Scientific Officer and director | $408,104 | $155,291 | $951,545 | $19,607 | $1,534,547 |
| Joshua HexterChief Operating & Business Officer | $259,038 | $93,992 | $608,545 | $69,875 | $1,031,450 |
What changed and why
- 15%15%: Compensation Committee increased NEO base salaries effective July 1, 2024.
- $1.2M$1,224,760: CEO RSU and PSU awards represented the largest component of his Fiscal 2024 compensation.
- Discretionary bonuses reflected scientific, business, financial and operational performance, with individual adjustments.
- Aon reviewed peer-company compensation and provided recommendations for cash and equity compensation.
- No specific formula determines the allocation between cash and non-cash compensation.
- 10%PSUs granted January 2, 2025 vest upon an HTIT joint venture or Scilex investment repayment plus 10%.
Other Oramed Pharmaceuticals proxy statements
- 2026 proxy statement
Nadav Kidron paid $4.8M (+128% on the year).
Filed Aug 03, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.